Alphyn Biologics Reports Positive Results from First Cohort of Phase 2a Trial of Mild-to-Moderate Atopic Dermatitis Treatment

Alphyn Biologics Reports Positive Results from First Cohort of Phase 2a Trial of Mild-to-Moderate Atopic Dermatitis Treatment NEWS PROVIDED BY Alphyn Biologics Jan 4, 2023, 07:30 ET ANNAPOLIS, Md. , Jan. 4, 2023 /PRNewswire/ — Alphyn Biologics , a clinical-stage dermatology company developing first-in-class multi-target therapeutics, announced today positive results from the first cohort of its Phase 2a clinical trial of AB-101a, a topical therapeutic for mild-to-moderate atopic dermatitis (AD). The trial met all of its primary endpoints, highlighting AB-101a’s potential to be an effective and safe treatment for AD. The randomized, vehicle-controlled, double-blind trial is evaluating the treatment protocol of AB-101a across multiple sites using standard scales for assessing AD. The trial, conducted in Australia , enrolled 41 AD patients, and treatment was evaluated after four weeks. “As a physician who treated 15 percent of the patients in the clinical trial, I am encouraged by the results with AB-101a,” said Dr. Stephen Shumack , Clinical Associate Professor Dermatology, University of Sydney , and Principal Investigator at St George Dermatology & Skin Cancer Centre. “I look forward to future trials and gaining a better understanding of AB-101a’s potential benefits for patients.” “Patients with mild-to-moderate atopic dermatitis suffer considerably from the symptoms of this often debilitating disease, yet available treatments come with side effects and safety concerns,” said Alphyn CEO Neal Koller . “We are excited by these results and look forward to the results of our ongoing cohort treating infected AD. We plan to further study AB-101a in a Phase 2b /3 trial this year in conjunction with a Series B financing.” Alphyn intends to present the full results of this trial at a scientific conference and submit a paper for publication in a peer-reviewed journal. Enrollment is ongoing in the second cohort of the Phase 2a clinical trial. This cohort is investigating the unique ability of AB-101a to treat the infected component of AD in AD patients who are suffering from bacterial infections, including Staphylococcus aureus , or “Staph,” and MRSA, the antibiotic-resistant Staph. Alphyn anticipates AB-101a will be effective in treating non-infected AD and infected AD. AB-101a should provide AD patients and physicians a comprehensive, safe, and convenient treatment option. AB-101a was developed using Alphyn’s proprietary AB-101 platform. The platform has multiple bioactive compounds and, therefore, multiple mechanisms of action to address multiple problems of any target disease. Alphyn was able to begin the AB-101a clinical trial program in Phase 2 due to the strong safety profile of its AB-101 platform. ABOUT ALPHYN BIOLOGICS Alphyn Biologics is a clinical-stage dermatology company developing first-in-class multi-target therapeutics for severe and prevalent skin diseases based on its AB-101 platform. Its lead product candidate, AB-101a, is being developed as a topical treatment for atopic dermatitis (AD), the most common form of eczema. AB-101a has demonstrated a strong safety profile and is in development to uniquely target AD’s immune system and bacterial components, making it ideal for treating AD and infected AD. Alphyn’s AB-101 platform has multiple bioactive compounds and therefore multiple mechanisms of action to support a robust pipeline of dermatologic therapeutics that have potential safety, efficacy and regulatory marketing authorization advantages. Alphyn is based in Annapolis, Maryland and Cincinnati, Ohio , and has a wholly owned Australia subsidiary. The company became operational in 2020 and has raised approximately $6.9 million . SOURCE Alphyn Biologics Link CONTACTS Corporate: Neal Koller [email protected] (410) 690-8687 Media: Susan Thomas [email protected] (619) 540-9195

The release as fetched from its publisher. alphynbiologics.com ↗